Clinical Analysis of Bloodstream Infection of Escherichia coli in Patients with Pancreatic Cancer from 2011 to 2019
Author(s) -
Changsen Bai,
Xiuse Zhang,
Dong Yang,
Li Ding,
Honglei Feng,
Yueguo Li
Publication year - 2022
Publication title -
canadian journal of infectious diseases and medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1918-1493
pISSN - 1712-9532
DOI - 10.1155/2022/1338188
Subject(s) - bloodstream infection , escherichia coli , pancreatic cancer , microbiology and biotechnology , medicine , bacteremia , cancer , biology , antibiotics , genetics , gene
Background. Pancreatic cancer patients were particularly predisposed to develop Escherichia coli (E. coli) bloodstream infection (BSI); however, little information is currently available. We set out to find E. coli BSI’s risk factors in pancreatic cancer to provide valuable experience. Methods. We retrospectively analyzed the clinical data of pancreatic cancer patients (31 cases with E. coli BSI and 93 cases without BSI) by a case-control study. SPSS 17.0 was adopted to perform univariate and multivariate analyses. Bacterial resistance analysis was performed by Whonet 5.6. Results. Hospitalization days ≥7 days, number of admissions ≥2 times, surgery, chemotherapy, the type of antibiotics used ≥2 species, albumin<40.0 g/L, and prealbumin < 0.2 g/L were the potential risk factors for pancreatic cancer patients with E. coli BSI ( P < 0.1 ). Multivariate logistic regression showed hospitalization days ≥7 days (OR = 11.196, 95% CI = 0.024–0.333, P < 0.001 ), surgery (OR = 32.053, 95% CI = 0.007–0.137, P < 0.001 ), and chemotherapy (OR = 6.174, 95% CI = 0.038–0.688, P = 0.014 ) were the independent risk factors for E. coli BSI of pancreatic cancer patients. E. coli resistant to carbapenems was rare; they were susceptible to cephamycin and piperacillin/tazobactam. The 90-day mortality rate of the infected group was significantly higher than the control group (41.9% versus 8.6%, P < 0.001 ). Conclusions. Hospitalization days ≥7 days, surgery, and chemotherapy are the independent risk factors for E. coli BSI of pancreatic cancer patients, which allows us to identify patients at potential risk and perform preventive treatment in time.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom